dendrobine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 442523 |
CHEMBL ID | 4173720 |
CHEBI ID | 4400 |
MeSH ID | M0042544 |
Synonym |
---|
C09943 , |
dendrobine |
a9n9fb9dpg , |
CHEBI:4400 |
AC-34706 |
AKOS030573402 |
HY-N0638 |
mfcd17676142 |
BCP13062 |
Q15410933 |
CS-0009667 |
(1s,4s,7s,8r,11r,12r,13s)-2,12-dimethyl-13-propan-2-yl-10-oxa-2-azatetracyclo[5.4.1.18,11.04,12]tridecan-9-one |
CHEMBL4173720 |
AS-80958 |
Dendrobine is an alkaloid isolated from Chinese herb Dendrobium nobile. It has knowing effects of analgesia and anti-inflammation.
Excerpt | Reference | Relevance |
---|---|---|
"Dendrobine is an alkaloid isolated from Chinese herb Dendrobium nobile, with knowing effects of analgesia and anti-inflammation." | ( Dendrobine attenuates osteoclast differentiation through modulating ROS/NFATc1/ MMP9 pathway and prevents inflammatory bone destruction. Chen, Y; Deng, W; Ding, Z; Ke, M; Li, X; Tan, Y; Wang, S; Wang, Y; Yang, Q; Zheng, J; Zou, B, 2022) | 2.89 |
"Dendrobine is a major alkaloid present mainly in dendrobium nobile Lindl. " | ( Metabolic Profile of Dendrobine in Rats Determined by Ultra-high-performance Liquid Chromatography/Quadrupole Time-of-flight Mass Spectrometry. Bai, JQ; Gong, L; Guo, QX; Huang, J; Huang, ZH; Li, JH; Luo, YB; Qiu, XH; Su, H; Xu, W; Zhang, J, 2021) | 2.38 |
Dendrobine has potential advantages in suppressing atherosclerosis (AS) It has been reported to reduce blood lipid levels and apoptosis.
Excerpt | Reference | Relevance |
---|---|---|
"Dendrobine has potential advantages in suppressing atherosclerosis (AS). " | ( Dendrobine modulates autophagy to alleviate ox-LDL-induced oxidative stress and senescence in HUVECs. Liang, Y; Lou, D; Xing, X, 2022) | 3.61 |
"Dendrobine has been reported to reduce blood lipid levels and apoptosis. " | ( Dendrobine suppresses endoplasmic reticulum stress-induced apoptosis through upregulating microRNA miR-381-3p to decrease caspase-4. Li, H; Lou, D; Meng, J; Song, X; Wang, H; Yan, G, 2021) | 3.51 |
Excerpt | Reference | Relevance |
---|---|---|
"Dendrobine can suppress inflammatory responses, oxidative stress, apoptosis, and senescence via FKBP1A-involved autophagy ox-LDL-treated HUVECs." | ( Dendrobine modulates autophagy to alleviate ox-LDL-induced oxidative stress and senescence in HUVECs. Liang, Y; Lou, D; Xing, X, 2022) | 2.89 |
Dendrobine significantly reduced Foxp3, and increased the level of IL-17 in serum. Treatment not only promoted the proliferation, but also inhibited the apoptosis of HUVECs induced by TM.
Excerpt | Reference | Relevance |
---|---|---|
"Dendrobine treatment not only promoted the proliferation, but also inhibited the apoptosis of HUVECs induced by TM." | ( Dendrobine suppresses endoplasmic reticulum stress-induced apoptosis through upregulating microRNA miR-381-3p to decrease caspase-4. Li, H; Lou, D; Meng, J; Song, X; Wang, H; Yan, G, 2021) | 2.79 |
"Treatment of dendrobine significantly reduced Foxp3, and increased the level of IL-17 in serum." | ( Synergism Effect of Dendrobine on Cisplatin in Treatment of H1299 by Modulating the Balance of Treg/Th17. Hou, P; Liu, G; Luo, Y, 2023) | 1.59 |
Excerpt | Reference | Relevance |
---|---|---|
" Cisplatin-based chemotherapy is the standard treatment for lung cancer, but chemoresistance and adverse effects especially cardiotoxicity limit its efficacy." | ( Dendrobine targeting JNK stress signaling to sensitize chemotoxicity of cisplatin against non-small cell lung cancer cells in vitro and in vivo. Chen, HY; Chen, XX; Feng, YB; Lee, CK; Li, ST; Ng, TB; Shi, J; Song, TH; Sze, SC; Wei, G; Xu, K; Yang, ZJ; Zhang, KY; Zhang, LY; Zhu, LL, 2019) | 1.96 |
Excerpt | Reference | Relevance |
---|---|---|
" The method was successfully applied to pharmacokinetic study of dendrobine after intravenous administration." | ( Pharmacokinetic study of dendrobine in rat plasma by ultra-performance liquid chromatography tandem mass spectrometry. Geng, P; Lin, Y; Liu, Z; Ma, J; Wang, S; Wang, X; Wen, C; Wu, H; Zhang, L; Zhou, Y, 2016) | 0.98 |
Class | Description |
---|---|
indoles | Any compound containing an indole skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1349617 | Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTS assay | |||
AID1349618 | Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTS assay | |||
AID1349615 | Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTS assay | |||
AID1349620 | Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production at 25 uM preincubated for 1 hr followed by LPS stimulation measured after 18 hrs by Griess assay | |||
AID1349614 | Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by MTS assay | |||
AID1349616 | Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTS assay | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 9 (20.00) | 18.7374 |
1990's | 3 (6.67) | 18.2507 |
2000's | 3 (6.67) | 29.6817 |
2010's | 11 (24.44) | 24.3611 |
2020's | 19 (42.22) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.44) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (2.22%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 44 (97.78%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |